Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study

D'Angelo S.;Tirri E.;Giardino A. M.;DeRosa T.;Matucci-Cerinic M.;Dagna L.;Santo L.;Ciccia F.;Frediani B.;Govoni M.;Pallavicini F. B.;Grembiale R. D.;Sedie A. D.;Mule R.;Cantatore F. P.;Foti R.;Gremese E.;Conigliaro P.;Salaffi F.;Viapiana O.;Cauli A.;Giacomelli R.;Arcarese L.;Guggino G.;Russo R.;Puenpatom A.;Capocotta D.;Nacci F.;Anelli M. G.;Picerno V.;Binetti C.;Iannone F.

2024-01-01